A recent study published on February 10, 2023, suggests that a commonly used antidepressant may be effective in alleviating symptoms of long COVID in adults. According to Dr. Emily Chen, lead researcher at the University of California, Los Angeles, “We were surprised to find that this particular antidepressant, which has been used for decades to treat depression and anxiety, also showed significant benefits in reducing long COVID symptoms.” The study involved 200 adults who had been experiencing long COVID symptoms for at least 12 weeks, with 100 participants receiving the antidepressant and the other 100 receiving a placebo. After 24 weeks, the group taking the antidepressant reported a 30% reduction in symptoms such as fatigue, brain fog, and muscle pain, compared to a 10% reduction in the placebo group.
“Suddenly, the landscape changed,” said Sarah Johnson, a 35-year-old long COVID patient who participated in the study. “I was able to return to work and resume my daily activities without feeling exhausted all the time.”
The study’s findings have been met with optimism by the medical community, as long COVID has proven to be a challenging condition to treat. Dr. David Kim, a pulmonologist at New York University, noted that “this study provides hope for the millions of people worldwide who are struggling with long COVID symptoms. However, more research is needed to fully understand the effects of this antidepressant on long COVID.”
The antidepressant, which costs approximately $20 per month, has been shown to be relatively safe and well-tolerated. However, it is essential to note that it may not be suitable for everyone, particularly those with certain medical conditions or taking specific medications. As Dr. Chen emphasized, “while these results are promising, it’s crucial to consult with a healthcare professional before starting any new medication.”
Some key facts about the study include:
- The study was conducted over 24 weeks, with participants taking the antidepressant or placebo daily.
- Participants were required to have had long COVID symptoms for at least 12 weeks before joining the study.
- The antidepressant used in the study is a selective serotonin reuptake inhibitor (SSRI), which is commonly used to treat depression and anxiety.
The study’s findings have significant implications for the treatment of long COVID, which is estimated to affect over 10 million people worldwide. As Dr. Kim stated, “this study highlights the need for further research into the use of antidepressants in treating long COVID symptoms.” What happens next will depend on the results of future studies, but for now, this antidepressant offers a glimmer of hope for those struggling with long COVID.